Immunotherapy for glioma: Current management and future application
Top Cited Papers
Open Access
- 7 February 2020
- journal article
- review article
- Published by Elsevier BV in Cancer Letters
- Vol. 476, 1-12
- https://doi.org/10.1016/j.canlet.2020.02.002
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81472693, 81873635)
- Natural Science Foundation of Hunan Province (2019JJ50963)
This publication has 156 references indexed in Scilit:
- Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastomaCancer Immunology, Immunotherapy, 2013
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastomaCancer Immunology, Immunotherapy, 2012
- Recent advances in the molecular understanding of glioblastomaJournal of Neuro-Oncology, 2012
- A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant gliomaJournal of Clinical Neuroscience, 2011
- Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapyJournal of Neuro-Oncology, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiformeBritish Journal of Cancer, 2009
- Genetically engineered T cells to target EGFRvIII expressing glioblastomaJournal of Neuro-Oncology, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Cytokines in cancer pathogenesis and cancer therapyNature Reviews Cancer, 2004